Figure 4. UA-4 elicited synergistic inhibition on cancer cells with glycolysis inhibitors and affects HepG2 cancer cell metabolism induced by 2-DG.
HepG2 (a) and L02 (b) cells were treated for 24 h with UA-4 at 4 μM and four glycolysis inhibitors (L-Cys: 15 mM; 2-DG: 50 mM; LM: 2.5 mM and 3-BrPA: 64 mM) at IC80. HepG2 (c) and L02 (d) cells were treated with compound UA-4 in the presence and absence of 2-DG followed by cell viability assay (*p < 0.05, **p < 0.01, #p < 0.05 and ##p < 0.01, compared to the combination groups).